Multiple Myeloma: An Interactive Discussion about CD38-Based Treatment in Newly Diagnosed Patients

Sanofi

Wednesday, 18.11.2026, 10:05- 10:25, Boston 1-2

Why is innovation still needed in hemophilia in 2026: meet the expert

Novo Nordisk

Wednesday, 18.11.2026, 10:05- 10:25, Kairo 1-2

Closing In on Cereblon: What’s Distinct About CELMoD Agents in Multiple Myeloma

Bristol-Myers Squibb SA

Wednesday, 18.11.2026, 15:20 - 15:40, Boston 1-2

Strategic Management of Platinum Resistant Ovarian Cancer. Aligning clinical practice with recent evidences.

AbbVie

Wednesday, 18.11.2026, 15:20 - 15:40, Dehli

Pirtobrutinib in CLL: Integrating the Latest Evidence from First-Line to Relapsed/Refractory Disease

Eli Lilly (Suisse) SA

Thursday, 19.11.2026, 10:05- 10:25, Darwin

The Expert View: Nirogacestat and Practical Safety Management in Desmoid Tumors

Merck

Thursday, 19.11.2026, 15:20 - 15:40, Darwin